How HALO Slip Proved Costly For CinCor In AstraZeneca Talks
Buyout Price Slashed After Baxdrostat Fail
Executive Summary
Hindsight is a wonderful thing but the saga of AstraZeneca's acquisition of CinCor is an eye-opener as SEC filings reveal that a $60 per share offer was rejected in September before a $26 bid won the day earlier this month.
You may also be interested in...
AZ And Boehringer Move Into Phase III With Rival Next-Gen CKD Drugs
Boehringer Ingelheim and AstraZeneca are once again going up against each other in chronic kidney disease, with Phase II results for their rival new agents showing promise. Unfortunately, they both also lie in the path of Novo Nordisk’s cardiometabolic juggernaut, Ozempic.
How The Allure Of Abivax Kept Marc de Garidel From The Beach
Abivax has had its ups and downs but newly appointed CEO Marc de Garidel tells Scrip he is confident that the French group is onto a winner with its ulcerative colitis drug, obefazimod.
How To Be An Early-Stage Biotech CEO In Challenging Times
The ongoing downturn is making early-stage biotech leaders work harder to gain funding – but new technology, business focus and better working practices could help them achieve success.